Next Article in Journal
Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope
Next Article in Special Issue
A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies
Previous Article in Journal
Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 8
Issue 1
10.3390/vaccines8010063
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review on Dengue Vaccine Development

by
Sheng-Qun Deng
1,†,
Xian Yang
1,†,
Yong Wei
1,
Jia-Ting Chen
1,
Xiao-Jun Wang
2 and
Hong-Juan Peng
1,*
1
Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China
2
Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Medical University, Dongguan 523808, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2020, 8(1), 63; https://doi.org/10.3390/vaccines8010063
Submission received: 31 December 2019 / Revised: 30 January 2020 / Accepted: 31 January 2020 / Published: 2 February 2020
(This article belongs to the Special Issue Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses)
Versions Notes

Abstract

Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.
Keywords: dengue virus; dengue fever; vaccine; vector-borne disease dengue virus; dengue fever; vaccine; vector-borne disease

Share and Cite

MDPI and ACS Style

Deng, S.-Q.; Yang, X.; Wei, Y.; Chen, J.-T.; Wang, X.-J.; Peng, H.-J. A Review on Dengue Vaccine Development. Vaccines 2020, 8, 63. https://doi.org/10.3390/vaccines8010063

AMA Style

Deng S-Q, Yang X, Wei Y, Chen J-T, Wang X-J, Peng H-J. A Review on Dengue Vaccine Development. Vaccines. 2020; 8(1):63. https://doi.org/10.3390/vaccines8010063

Chicago/Turabian Style

Deng, Sheng-Qun, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang, and Hong-Juan Peng. 2020. "A Review on Dengue Vaccine Development" Vaccines 8, no. 1: 63. https://doi.org/10.3390/vaccines8010063

APA Style

Deng, S.-Q., Yang, X., Wei, Y., Chen, J.-T., Wang, X.-J., & Peng, H.-J. (2020). A Review on Dengue Vaccine Development. Vaccines, 8(1), 63. https://doi.org/10.3390/vaccines8010063

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop